A fecal transplant, formally called fecal microbiota transplantation (FMT), is a medical procedure that transfers a small sample of stool from a healthy donor into the gut of a sick patient. The goal is to repopulate the patient’s intestines with a diverse community of beneficial microorganisms. Right now, it is recommended and proven effective for one condition: recurrent Clostridioides difficile (C. diff) infection, a stubborn bacterial infection of the colon that resists standard antibiotic treatment.
Why Transplanting Stool Works
Your gut is home to trillions of bacteria, fungi, and viruses that work together to digest food, regulate your immune system, and keep harmful organisms in check. When this ecosystem gets disrupted, often by repeated rounds of antibiotics, dangerous bacteria like C. diff can take over. The antibiotics meant to kill the infection also wipe out the protective bacteria, creating a cycle where C. diff keeps coming back.
FMT breaks that cycle by reintroducing a full, functioning microbial community. Donor stool contains not just bacteria but also fungi, viruses, and the chemical byproducts these organisms produce. Researchers have identified certain “keystone” species, including members of the Ruminococcus, Bifidobacterium, and Prevotella families, that play an outsized role in restoring balance. These species break down complex dietary fibers and produce short-chain fatty acids, compounds that nourish the colon lining and make the environment inhospitable to C. diff. Some donors are so consistently effective that researchers have coined the term “super-donors” to describe people whose gut bacteria correlate with higher rates of clinical remission.
How Effective It Is
FMT works significantly better than antibiotics alone for recurrent C. diff. In studies, the one-month success rate sits around 79 to 80 percent. At one year, roughly 68 to 70 percent of patients remain free of recurrence. For comparison, the standard antibiotics used against C. diff (vancomycin and fidaxomicin) succeed about 73 percent and 63 percent of the time respectively, and both carry high recurrence rates. The difference is especially meaningful for people who have already failed multiple courses of antibiotics and are caught in a relentless cycle of infection.
How the Procedure Is Done
There are several ways to deliver donor stool into a patient’s gut, and the choice depends on clinical factors like the severity of infection, the patient’s overall health, and what the treating physician recommends.
- Colonoscopy: The donor material is delivered directly into the colon during a standard colonoscopy. This is one of the most common methods and allows the physician to examine the colon at the same time.
- Oral capsules: Capsules containing processed donor stool are swallowed by the patient. This is the least invasive option and can be done without a hospital procedure. The FDA-approved product Vowst, for example, involves four capsules taken once daily for three consecutive days.
- Upper GI routes: In some cases, donor material is delivered through a tube inserted through the nose into the stomach or small intestine.
- Enema: A retention enema delivers the material into the lower colon. This method is simpler than colonoscopy but may not reach as far into the intestine.
Capsules have become the most commonly used delivery method. Interestingly, success rates with standard oral capsules and colon-targeted capsules are similar, suggesting that enough beneficial microbes survive passage through stomach acid to do their job. Patient comfort, cost, and the number of repeat treatments needed all factor into which approach a physician recommends.
FDA-Approved Products
The FDA has approved two fecal microbiota products specifically to prevent recurrent C. diff. The most notable is Vowst, the first orally administered fecal microbiota product, approved for adults 18 and older who have already completed antibiotic treatment for recurrent C. diff. Before these approvals, FMT was performed using stool sourced from donors and prepared at hospitals or stool banks, a practice that still occurs but carries less regulatory standardization.
Donor Screening and Safety
Donor screening is intensive because transferring someone else’s stool means transferring everything living in it, including potentially dangerous organisms. The FDA requires that donor stool be tested using sensitive genetic detection methods for harmful bacteria, including certain strains of E. coli that produce toxins. Stool samples are tested both before and after donation periods, no more than 60 days apart, and product batches are quarantined until both tests come back clean.
At a minimum, donors must also be screened for antibiotic-resistant organisms: ESBL-producing bacteria, vancomycin-resistant enterococci, carbapenem-resistant bacteria, and MRSA. These screening requirements exist because of real consequences. In a widely reported case, two immunocompromised patients received FMT prepared from the same donor whose stool had not been tested for antibiotic-resistant organisms. Both developed serious invasive infections from drug-resistant E. coli. One of them died. When the remaining stored material from that donor was later tested, it came back positive for the same resistant bacteria found in both patients.
Common Side Effects
Most people tolerate FMT well, but mild gastrointestinal symptoms are common in the days following the procedure. These typically include bloating, cramping, gas, and changes in bowel habits. The side effects tend to resolve on their own. The more serious risks, like transmission of drug-resistant infections, are rare but underscore why donor screening is so rigorous. People with weakened immune systems face higher risk from any transmitted organisms, and informed consent for the procedure now specifically addresses the possibility of antibiotic-resistant infection.
What It Costs
Cost is one of the less straightforward parts of FMT. According to the American Gastroenterological Association, there is no standard “fee” for the transplant itself, but the costs associated with the procedure (colonoscopy, hospital time, or the FDA-approved capsule products) vary. Donor screening tests alone can run several hundred dollars, and donors should be aware their own insurance may not cover those costs. Insurance coverage for the recipient’s procedure depends on the plan and whether FMT is being used for an FDA-recognized indication like recurrent C. diff.
What FMT Does Not Treat (Yet)
There is enormous interest in using FMT for conditions beyond C. diff, including inflammatory bowel disease, obesity, autism, and even certain cancers. Early research has explored how the microbial byproducts in donor stool might influence bile acid metabolism, immune cell function, and inflammation throughout the body. But as of now, there is no scientific evidence that fecal transplant is safe and effective for any of these conditions. The only proven, recommended use remains recurrent C. diff infection that has not responded to standard antibiotic treatment.